Genome-Editing: The Value of CRISPR’s Intellectual Property
The CRISPR IP landscape can often seem like a labyrinth. ARK aims to summarize the key CRISPR stakeholders and collaborations, including: i) licenses from patent holders, ii) sub-licenses from surrogates to collaborators, iii) areas of CRISPR research, and iv) exclusive vs. non-exclusive licenses.
ARK believes the IP battle will result in cross-licensing agreements and the global proliferation of CRISPR technology. While it may be years until we have a resolution, the benefits of CRISPR are already tangible. To download the full white paper, please fill out the form.
You also may be interested in our white paper: